EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
|
EQS-Ad-hoc: FamiCord AG / Key word(s): Annual Results/Forecast FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures Leipzig, 10 April 2025 – FamiCord AG has significantly exceeded its earnings guidance for the 2024 financial year. This is the conclusion reached by the Management Board on the basis of the preliminary business figures available today. Based on these preliminary figures, revenue amounted to EUR 82.2 million and earnings before interest, taxes, depreciation and amortization (EBITDA) to EUR 8.8 million. As part of the guidance for the 2024 financial year, the Management Board expected revenue of between EUR 81 million and EUR 88 million and EBITDA of between EUR 6.5 million and EUR 8.0 million. The deviation in earnings from the upper end of the guidance range is therefore around 10 percent. Notifying Person: Jakub Baran (CEO) --- End of inside information according to Art. 17 MAR --- End of Inside Information Information and Explanation of the Issuer to this announcement: The Company will publish the full 2024 annual report as planned on 30 April 2025.
FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord. Furthermore, the Company is active in the areas of Cell & Gene therapies and CDMO.
10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | FamiCord AG |
| Perlickstr. 5 | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@famicord.com |
| Internet: | www.famicord.com |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2115580 |
| End of Announcement | EQS News Service |
|
|
2115580 10-Apr-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 19,93 | 20,07 | 28,42 | 68,94 | 77,06 | 82,20 | 0,00 | |
| EBITDA1,2 | 5,43 | 5,34 | 0,81 | -3,56 | 5,57 | 8,80 | 0,00 | |
| EBITDA-Margin3 | 27,25 | 26,61 | 2,85 | -5,16 | 7,23 | 10,71 | 0,00 | |
| EBIT1,4 | 2,45 | 2,38 | -3,07 | -27,28 | -3,12 | -1,20 | 0,00 | |
| EBIT-Margin5 | 12,29 | 11,86 | -10,80 | -39,57 | -4,05 | -1,46 | 0,00 | |
| Net Profit (Loss)1 | 0,72 | 1,50 | -3,93 | -27,38 | -2,03 | -2,90 | 0,00 | |
| Net-Margin6 | 3,61 | 7,47 | -13,83 | -39,72 | -2,63 | -3,53 | 0,00 | |
| Cashflow1,7 | 6,32 | 3,98 | 2,73 | -4,49 | 9,15 | 0,00 | 0,00 | |
| Earnings per share8 | 0,18 | 0,37 | -0,63 | -1,71 | -0,12 | -0,16 | -0,08 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| FamiCord | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0BL84 | DE000A0BL849 | AG | 72,68 Mio € | 27.03.2007 | Halten | 9F3J899W+W5 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 29,43 | 36,92 | 0,80 | -35,83 | 3,19 | 7,94 | 0,88 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.06.2025 | 28.05.2025 | 27.08.2025 | 22.11.2024 | 30.04.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,91% | -3,78% | +0,00% | -8,44% | -72,53% |
